Trial Profile
Effect of Raltegravir in Patients With Myelopathy/Tropical Spastic Paraparesis Associated With Infection by Human T-Lymphotropic Virus 1 (HTLV-1). Pilot Study
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary) ; Zidovudine (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 20 May 2019 Status changed from recruiting to completed.
- 20 Nov 2017 Planned End Date changed from 1 Jun 2018 to 1 Jun 2019.
- 20 Nov 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Jun 2018.